[WATRMC 2018] How are insurers adapting to the unique challenges posed by biobanks?

In this interview, filmed at the World Advanced Therapies and Regenerative Medicine Congress (16–18 May, London, UK), Alan Stokes, COO, Future Family, discusses how insurers can work with biobanks and patients to ensure adequate reimbursement.

Go to the profile of RegMedNet
May 17, 2018
1
1
Upvote 1 Comment

As part of the World Advanced Therapies and Regenerative Medicine Congress (16–18 May, London, UK) Interview Zone, RegMedNet Editor Freya Leask spoke to Alan Stokes, COO, Future Family (London, UK). In this interview, Alan discusses the challenges of insuring and reimbursing advanced therapies, and the importance of making sure patients are fully informed.

Find out more about the World Advanced Therapies and Regenerative Medicine Congress on their website.

Go to the profile of RegMedNet

RegMedNet

eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

1 Comments

Go to the profile of James L. Sherley, M.D., Ph.D.
James L. Sherley, M.D., Ph.D. about 2 months ago

Excellent, very informative interview about an crucial element of the developing worldwide stem cell treatment industry.  In the U.S., a cord blood HSC transplant for childhood leukemia can cost as much as $200,000 USD.  Unfortunately, about 18% or more of these treatments fail because of uncertainty of the potency of the treating CB sample.  Insurers should also have an interest in promoting the adoption of new CB banking technologies that reduce this uncertainty.


James Sherley

Asymmetrex